Stock of the Day for January 5, 2025

Abbott Laboratories Stock Report

Abbott Laboratories
ABT 90-day performance NYSE:ABT Abbott Laboratories
Current Price
$133.90
+1.14 (+0.86%)
(As of 03:59 PM ET)
30 Day Performance
2.75%
  
 
90 Day Performance
1.17%
  
 
1 Year Performance
13.35%
  
 
Market Capitalization
$233.05B
P/E Ratio
16.78
Dividend Yield
1.76%

About Abbott Laboratories

Abbott Laboratories (NYSE: ABT) is a global healthcare company headquartered in Abbott Park, Illinois. Founded in 1888 by Wallace C. Abbott, the company has grown into a diversified provider of diagnostics, medical devices, nutritionals and established pharmaceuticals. Abbott’s longstanding heritage in healthcare research and innovation has shaped its mission to improve lives through the advancement of science and technology.

In its diagnostics segment, Abbott offers a broad range of laboratory and point-of-care testing solutions, covering areas such as infectious diseases, diabetes monitoring, immunoassays and molecular diagnostics. The medical devices unit develops products for cardiovascular care, neuromodulation and structural heart interventions, including coronary stents, transcatheter heart valves and implantable neurostimulation systems. Through its nutrition division, Abbott supplies both pediatric and adult nutritional products, with well-known brands designed to support growth, recovery and wellness. The established pharmaceuticals business markets branded generic medicines across emerging markets, addressing therapeutic areas like women’s health, cardiovascular disease and central nervous system disorders.

Abbott serves customers in more than 160 countries worldwide, with manufacturing facilities, R&D centers and distribution networks strategically located across the Americas, Europe, Asia Pacific and other regions. This geographical reach enables the company to tailor its product offerings to local market needs, collaborate with regional healthcare providers and respond swiftly to public health challenges. Abbott’s supply chain and regulatory expertise support its commitment to maintaining high quality standards and ensuring access to critical healthcare solutions.

Under the leadership of President and Chief Executive Officer Robert B. Ford, who assumed the role in early 2020, Abbott continues to focus on innovation-driven growth and expanding its portfolio of life-changing technologies. The company’s executive team comprises seasoned professionals with deep experience in research and development, global operations and regulatory affairs. With a workforce of over 114,000 employees worldwide, Abbott remains dedicated to advancing health care through scientific excellence, collaboration and a commitment to improving patient outcomes.

ABT Company Calendar

JUL. 15, 2025
Ex-Dividend for 8/15 Dividend
JUL. 17, 2025
Last Earnings
AUG. 15, 2025
Dividend Payable
SEP. 17, 2025
Today
OCT. 15, 2025
Next Earnings (Estimated)
DEC. 31, 2025
Fiscal Year End

Recent Abbott Laboratories News

Is Abbott Laboratories (NYSE:ABT) Using Too Much Debt?
Fiduciary Alliance LLC Buys 3,610 Shares of Abbott Laboratories $ABT
Czech National Bank Acquires 26,900 Shares of Abbott Laboratories $ABT
Abbott Laboratories $ABT Shares Sold by MassMutual Private Wealth & Trust FSB
Little House Capital LLC Has $1.03 Million Holdings in Abbott Laboratories $ABT
Rep. Julie Johnson Sells Off Shares of Abbott Laboratories (NYSE:ABT)
This report was written by MarketBeat.com on September 17, 2025. This report first appeared on MarketBeat.com.